Insider Selling: Gilead Sciences CFO Sells 6,426 Shares of Stock (GILD)
Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington sold 6,426 shares of the stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $82.52, for a total transaction of $530,273.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Gilead Sciences (NASDAQ:GILD) traded down 0.26% on Thursday, hitting $82.80. The stock had a trading volume of 8,423,695 shares. Gilead Sciences has a 52 week low of $46.70 and a 52 week high of $84.88. The stock’s 50-day moving average is $78.99 and its 200-day moving average is $76.68. The company has a market cap of $127.2 billion and a price-to-earnings ratio of 30.75.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $1.48 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The company’s quarterly revenue was up 97.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $6.22 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, May 29th. Separately, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $135.00 to $142.00 in a research note on Wednesday, May 28th. Finally, analysts at Zacks upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating in a research note on Friday, May 23rd. They now have a $99.00 price target on the stock. Two analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and an average price target of $90.12.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.